Postnatal Depression

The period after having a baby is commonly portrayed as a time of uncomplicated happiness. The clinical reality is more nuanced. Emotional and psychological difficulties in the weeks and months after birth are common — and exist on a spectrum, from the short-lived adjustment known as the baby blues, through to postnatal depression, and in rare cases to the psychiatric emergency of postpartum psychosis (a rare, severe condition involving breaks from reality, hallucinations, or delusions).

Understanding these three distinct clinical entities matters, because the appropriate response to each is very different:

1. Baby blues — a brief, self-limiting period of low mood, tearfulness, and emotional sensitivity in the first days after birth, caused by the rapid fall in oestrogen (the primary female hormone, which surges during pregnancy) and progesterone (another pregnancy hormone). Baby blues affect the majority of new mothers and typically resolve within two weeks without clinical treatment.
2. Postnatal depression (PND) — a clinical depressive disorder beginning during pregnancy or in the first year after birth. It is distinct from the baby blues in its duration, severity, and impact on everyday functioning. PND does not resolve on its own without treatment — it requires clinical recognition and support. Without this, symptoms can persist for months and worsen.
3. Postpartum psychosis — a rare but serious psychiatric emergency that can develop rapidly, usually within the first two weeks after birth. Symptoms include hallucinations (perceiving things that are not there), delusions (firmly held false beliefs), extreme confusion, and severely disrupted behaviour. Postpartum psychosis requires urgent medical assessment and is clinically recognised as time-sensitive — 111 or urgent GP access exists for this presentation.

This article focuses on postnatal depression — the most common of these three conditions, the least well-recognised in practice, and the one most affected by stigma and misinformation. NICE CG192 — the national guideline on antenatal and postnatal mental health — provides the clinical framework used across the UK for recognition, assessment, and treatment.^[1]

Postnatal depression can present in a wide range of ways. It is not simply "feeling sad after having a baby." Symptoms include persistent low mood, difficulty finding pleasure in activities, fatigue (extreme physical or mental tiredness) disproportionate to sleep disruption, difficulty bonding with the baby, excessive anxiety (particularly about the baby's health or safety), feelings of worthlessness or guilt, and intrusive thoughts — distressing, unwanted thoughts that the individual does not wish to act on. Anger and irritability are also common presentations, particularly in those who do not fit the stereotyped picture of tearfulness.

Postnatal depression matters at a population level because it is common, because it is associated with serious consequences for mothers, partners, and infants when unrecognised or untreated, and because stigma remains a significant barrier to help-seeking. MBRRACE-UK — the national confidential enquiry into maternal deaths, funded by NHS England and conducted by the National Perinatal Epidemiology Unit at the University of Oxford — publishes detailed data on maternal mortality in the UK. Its most recent report (covering 2022–24) confirms that maternal suicide remains the leading cause of late maternal death — those occurring between six weeks and one year after the end of pregnancy — and that psychiatric causes as a whole account for 33% of all late maternal deaths.^[2] These are not marginal statistics. They reflect a public health problem of significant scale that has been consistently highlighted across successive MBRRACE reports.

Beyond the most severe outcomes, postnatal depression carries a substantial burden on everyday life. Women with PND frequently describe struggling with the basic tasks of new parenthood — feeding, settling, responding to a baby's cues — at precisely the time when those tasks feel most critical. The condition impairs maternal sensitivity and responsiveness, which in turn affects the mother-infant bond (the close emotional attachment between parent and baby that develops in the first months of life) and has well-documented consequences for the baby's emotional, social, and cognitive development.

PND also affects partners — including fathers, non-birth parents, and adoptive parents — who can develop postnatal depression in response to the demands, sleep disruption, and relationship changes that follow the arrival of a new baby. NICE CG192 explicitly recognises the need to assess and support partners as well as birth mothers.^[1]

The condition is also significantly under-recognised. The postpartum period is socially constructed as a time of joy. Women who do not feel that joy — who feel exhausted, detached, anxious, or angry — frequently describe feeling unable to speak about it for fear of being judged as ungrateful or inadequate. This silence perpetuates underdiagnosis. Clinical screening at standardised time points exists precisely to create an opportunity to ask the question without requiring a woman to volunteer a disclosure.

Identification and screening

NICE CG192 recommends that all women are asked about their mental health and emotional wellbeing at their booking appointment (the first antenatal appointment, usually at 8–10 weeks of pregnancy) and during the early postnatal period — typically at the 6-week postnatal check with a GP, or at health visitor contacts in the weeks following birth.^[1] The initial identification tool used is the Whooley questions (see Key Terms) — two standardised questions about low mood and loss of interest or pleasure. A positive response to either question triggers further assessment.

The Edinburgh Postnatal Depression Scale (EPDS — see Key Terms) is the validated 10-question screening tool used for full assessment. It covers the core domains of depression as they present in the perinatal period, including anxiety, inability to enjoy things, tearfulness, feelings of being overwhelmed, and thoughts of self-harm. A score of 13 or above indicates probable depression requiring further clinical assessment and support. Health visitors are trained to administer and interpret the EPDS at standardised contact points in the first weeks after birth.

Mild to moderate postnatal depression

For mild to moderate PND, NICE CG192 recommends psychological therapies as first-line treatment.^[1] These include:

• •CBT (cognitive behavioural therapy — see Key Terms) — individual or group format; focuses on identifying and challenging unhelpful thinking patterns and behaviours that maintain low mood
• •IPT (interpersonal therapy — see Key Terms) — focuses on relationship changes and life transitions, making it particularly suited to the postnatal period where the transition to parenthood is often central to the presentation
• •Supported self-help — structured self-help materials, delivered with support from a trained practitioner, as a first step where access to therapy is limited

In the UK, these therapies are available through NHS Talking Therapies (formerly IAPT — Improving Access to Psychological Therapies) via GP referral, or directly through self-referral in many areas. Waiting times vary by region.

Moderate to severe postnatal depression

For moderate to severe PND, NICE CG192 recommends antidepressant medication — either alone or in combination with psychological therapy — depending on the woman's history, preferences, and the severity of her presentation.^[1] The most commonly used antidepressant in the UK perinatal period is Lustral (sertraline) — an SSRI (see Key Terms) — which has the most established safety data in this context and transfers into breast milk at very low levels. The choice of medication takes into account the woman's previous response to antidepressants if she has taken them before, breastfeeding status, and individual circumstances. NICE CG192 emphasises that treatment decisions should be made in partnership, with full information about the benefits and risks of treatment compared with the risks of untreated depression.

Severe postnatal depression and postpartum psychosis

Women with severe PND, or any presentation involving postpartum psychosis (see Key Terms), should be referred to specialist perinatal mental health services — multidisciplinary teams with specific expertise in perinatal mental illness. Where admission is needed, admission to a mother and baby unit (MBU — a specialist inpatient psychiatric unit designed to keep mother and baby together during treatment) is the appropriate pathway, rather than a general psychiatric ward where the baby cannot be present.^[1] This is clinically recognised as important for maintaining the mother-infant bond and supporting breastfeeding where applicable.

Medication and breastfeeding

NICE CG192 is explicit that medication decisions in breastfeeding women require full discussion of the benefits and risks — not automatic exclusion of medication.^[1] The evidence base for the safety of Lustral (sertraline) during breastfeeding is well-established; it is widely regarded as the first-line SSRI choice in this context. Fluoxetine (Prozac) — another SSRI — is generally avoided as it accumulates more in breast milk. The principle is that untreated severe maternal depression carries its own risks to both mother and infant, and these must be weighed against medication risks on an individual basis.

Partner mental health

NICE CG192 recommends that the mental health needs of partners are also assessed and addressed as part of perinatal care.^[1] Partners who are experiencing depression or anxiety themselves should be offered the same pathways — GP assessment, referral to NHS Talking Therapies, or specialist perinatal services where needed. Paternal postnatal depression is clinically recognised and is not dependent on the birth mother being affected, though the risk is higher when the birth parent also has PND.